LUNG CANCER

An easy way to double survival for patients with lung cancer is by removing the barriers to screening.

Datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy showed promising efficacy and a manageable safety profile in advanced/metastatic non–small cell lung cancer without actionable genomic alterations.

Pembrolizumab and etoposide continues to demonstrate improvements in survival outcomes compared with placebo and etoposide in patients with previously untreated extensive stage-small cell lung cancer.

During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.

Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.

Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.

Atezolizumab may lead to improved overall survival when compared with the best supportive care in patients with resected non–small cell lung cancer.

Pembrolizumab plus lenvatinib demonstrated promising clinical activity with no unexpected toxicities in patients with malignant pleural mesothelioma, according to results from the PEMMELA study.

Comparable outcomes seen with sintilimab vs pembrolizumab in patients with treatment-naïve metastatic non–small cell lung cancer.

Unique signaling pathways and significant differentially-expressed genes was found from 4 subgroups of patients with MET exon 14 skipping non–small cell lung cancer.

Treatment with concurrent sugemalimab demonstrated prolonged progression-free survival in patients with stage III unresectable non–small cell lung cancer.

Using neoadjuvant chemoimmunotherapy to treat patients with stage IIIA resectable non–small cell lung cancer based on differences between pathologic complete responders and non–pathologic complete responders is supported by the phase 2 NADIM trial.

Sacituzumab govitecan-hziy vs single-agent docetaxel with be evaluated in the phase 3 EVOKE-01 trial of patients with metastatic non–small cell lung cancer.

Overall survival benefit was sustained with second- or third-line tislelizumab in patients with non–small cell lung cancer vs docetaxel in the final analysis of the phase 3 RATIONALE-303 trial.

The phase 2 Neo-KAN study revealed neoadjuvant adagrasib alone or in combination with nivolumab may improve pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer.

First-line durvalumab in combination with tremelimumab improved overall survival vs standard-of-care chemotherapy for the treatment of patients with metastatic non–small cell lung cancer.

Larotrectinib continued to demonstrate favorable efficacy and survival outcomes with low toxicity, according to extended follow-up for 2 trials of patients with lung cancer and NTRK fusions.

In the first installment of the series, Allison Betof Warner, MD, PhD, reviews the mechanistic rationale behind tumor-infiltrating lymphocytes and considers where these experimental therapies may fit in the oncologic landscape.

During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.

In the phase 3 IMscin001 clinical trial, the use of subcutaneous atezolizumab demonstrated similar efficacy, safety, and pharmacokinetics compared with intravenous atezolizumab in patients with immunotherapy-naïve locally advanced or metastatic non—small cell lung cancer.

Although lung cancer screening rates are currently low, identifying the obstacles and potential solutions may raise the number of screenings in the United States.

During a live virtual event, Martin F. Dietrich, MD, PhD, discussed the results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials of cemiplimab for non–small cell lung cancer.

Findings from the ALCHEMIST trial indicate 53% of patients received adequate lymph node dissection and only 57% received adjuvant chemotherapy, despite indications for this treatment.

At a live virtual event, Devika Das, MD, discussed the use of immunotherapy for patients with extensive stage-small cell lung cancer (ES-SCLC) and for patients with non–small cell lung cancer.

Alexander Drilon, MD, discusses the differences in how TRK fusions manifest in older patients vs younger patients.

During a live virtual event, Adam M. Schoenfeld, MD, discussed results of the KEYNOTE-407 trial of patients with advanced squamous non–small cell lung cancer in terms of PD-L1 expression. This is the second of 2 articles based on this event.

The phase 2 THIO-101 clinical trial evaluating THIO in combination with cemiplimab in patients with advanced non—small cell lung cancer has dosed its first patient.

In an interview with Targeted Oncology, Mary O’Brien, MD, discussed background of the second interim analysis of the triple-blind, phase 3 PEARLS/KEYNOTE-091 study.

Nathan A. Pennell, MD, PhD, discusses the study design and goals of an ongoing phase 1 trial of a novel RET inhibitor for patients with non–small cell lung cancer and medullary thyroid cancer.

During a live virtual event, Christine Bestvina, MD, discussed the use of amivantamab and mobocertinib, 2 new targeted therapies for patients with non–small cell lung cancer and an EGFR exon 20 insertion.